OverviewSuggest Edit

TCR , Inc. is a discovery stage pharmaceutical company focused on engineering T cells for cancer therapy. The company's vast expertise in T cell engagement and a deep understanding of T cell receptor biology enabled the creation of a novel first-in-class approach that is highly differentiated from CAR-T cells and from T cells engineered to express defined TCR alpha/beta chains. TCR was founded by MPM Capital and has scientific operations in Kendall Square, Cambridge, Massachusetts to leverage best-in-class technologies and nucleate top-tier academic laboratories around the world.
TypePublic
Founded2015
HQCambridge, US
Websitetcr2.com

Latest Updates

Employees (est.) (Feb 2019)44(+5%)
Job Openings8
Share Price (May 2020)$11.5 (-1%)

Key People/Management at TCR2 Therapeutics

Garry Menzel

Garry Menzel

President and Chief Executive Officer
Robert Hofmeister

Robert Hofmeister

Chief Scientific Officer
Angela Justice

Angela Justice

Chief People Officer
Ian Somaiya

Ian Somaiya

Chief Financial Officer
Robert Tighe

Robert Tighe

Vice President of Translational Research
Stephen Turkowiak

Stephen Turkowiak

Vice President of Finance
Show more

TCR2 Therapeutics Office Locations

TCR2 Therapeutics has an office in Cambridge
Cambridge, US (HQ)
100 Binney St #710
Show all (1)

TCR2 Therapeutics Financials and Metrics

TCR2 Therapeutics Revenue

USD

Net income (Q1, 2020)

(15.5m)

EBIT (Q1, 2020)

(16.2m)

Market capitalization (27-May-2020)

277.8m

Closing stock price (27-May-2020)

11.5

Cash (31-Mar-2020)

31.1m
TCR2 Therapeutics's current market capitalization is $277.8 m.
Annual
USDFY, 2016FY, 2017FY, 2019

General and administrative expense

2.3m3.6m13.9m

R&D expense

7.7m9.6m37.5m

Operating expense total

9.9m13.2m51.4m

EBIT

(9.9m)(13.1m)(51.4m)
Quarterly
USDQ1, 2019Q2, 2019Q3, 2019Q1, 2020

General and administrative expense

2.9m3.3m3.5m4.3m

R&D expense

7.9m8.8m11.4m12.0m

Operating expense total

10.8m12.1m14.9m16.2m

EBIT

(10.8m)(12.1m)(14.9m)(16.2m)
Annual
USDFY, 2016FY, 2017FY, 2019

Cash

8.0m19.8m65.3m

Prepaid Expenses

975.0k892.0k5.1m

Current Assets

17.3m20.7m163.2m

PP&E

936.0k1.0m4.9m
Quarterly
USDQ1, 2019Q2, 2019Q3, 2019Q1, 2020

Cash

46.4m41.0m49.3m31.1m

Prepaid Expenses

3.9m6.1m5.6m6.8m

Current Assets

165.6m175.7m166.6m133.0m

PP&E

1.9m3.2m4.5m5.2m
Annual
USDFY, 2016FY, 2017FY, 2019

Net Income

(9.9m)(13.1m)(47.6m)

Depreciation and Amortization

220.0k298.0k862.0k

Accounts Payable

76.0k(101.0k)(179.0k)

Cash From Operating Activities

(9.4m)(12.0m)(41.4m)
Quarterly
USDQ1, 2019Q2, 2019Q3, 2019Q1, 2020

Net Income

(9.9m)(21.0m)(34.8m)(15.5m)

Depreciation and Amortization

135.0k300.0k558.0k306.0k

Accounts Payable

(401.0k)180.0k489.0k603.0k

Cash From Operating Activities

(10.8m)(21.0m)(31.0m)(16.4m)
USDY, 2020

Financial Leverage

1 x
Show all financial metrics

TCR2 Therapeutics Acquisitions / Subsidiaries

Company NameDateDeal Size
TRUC Securities Corporation
TRUCS Therapeutics Limited

TCR2 Therapeutics Online and Social Media Presence

Embed Graph

TCR2 Therapeutics News and Updates

TCR2 Therapeutics Announces First Quarter 2019 Earnings Conference Call and Webcast

CAMBRIDGE, Mass., April 29, 2019 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (TCR2) (Nasdaq: TCRR), a clinical-stage immunotherapy company developing the next generation of novel T cell therapies for patients suffering from cancer, today announced that it will release results for the first quarter …

TCR2 Therapeutics Presents Preclinical Data on its Lead Solid Tumor and Blood Cancer Programs at the American Association for Cancer Research (AACR) Annual Meeting

CAMBRIDGE, Mass., March 28, 2019 /PRNewswire/ -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company developing the next generation of novel T cell receptor (TCR) therapies for patients suffering from cancer, today announced that preclinical data on its lead...

TCR2 Therapeutics Announces Exercise of Over-Allotment Option

CAMBRIDGE, Mass., Feb. 26, 2019 /PRNewswire/ -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company developing the next generation of novel T cell receptor (TCR) therapies for patients suffering from cancer, today announced that the underwriters of its recent...

TCR2 Therapeutics Announces Pricing of Initial Public Offering of Common Stock

CAMBRIDGE, Mass., Feb. 13, 2019 /PRNewswire/ -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company developing the next generation of novel T cell receptor (TCR) therapies for patients suffering from cancer, today announced the pricing of the Company's initial...

TCR2 Therapeutics Launches Proposed Initial Public Offering

CAMBRIDGE, Mass., Feb. 1, 2019 /PRNewswire/ -- TCR2 Therapeutics Inc., a clinical-stage immunotherapy company developing the next generation of novel T cell receptor therapies for patients suffering from cancer, today announced that it has launched an underwritten initial public offering...

TCR2 Therapeutics files for IPO

TCR2 Therapeutics filed for an initial public offering on Friday, with plans to list on Nasdaq under the ticker symbol "TCRR". Jefferies, Leerink, BMO, Wedbush and China Renaissance are underwriters on the deal. The company said it's aiming to raise $100 million, but that number is likely a placehol…
Show more

TCR2 Therapeutics Blogs

TCR² Therapeutics to Present an Allogeneic Construct at the Keystone Symposia Conference on Emerging Cellular Therapies: Cancer and Beyond

CAMBRIDGE, Mass. , Feb. 03, 2020 (GLOBE NEWSWIRE) -- TCR 2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company developing the next generation of novel T cell therapies for patients suffering from cancer, today announced that it will present a poster at the 2020 Keystone

TCR² Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass. , Jan. 07, 2020 (GLOBE NEWSWIRE) -- TCR 2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company developing the next generation of novel T cell therapies for patients suffering from cancer, today announced that Garry Menzel , Ph.D., President and Chief Executive

TCR² Therapeutics Reports Third Quarter 2019 Financial Results and Provides Corporate Update

CAMBRIDGE, Mass. , Nov. 12, 2019 (GLOBE NEWSWIRE) -- TCR 2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company developing the next generation of novel T cell therapies for patients suffering from cancer, today announced financial results for the third quarter ended September

TCR² Therapeutics Appoints Industry Veteran Angela Justice, Ph.D., as Chief People Officer

TCR² Therapeutics Appoints Industry Veteran Angela Justice, Ph.D., as Chief People Officer Katherine.Howe… Wed, 10/09/2019 - 06:30 TCR² Therapeutics Appoints Industry Veteran Angela Justice, Ph.D., as Chief People Officer Oct 09, 2019 This release is a backfill from a…

TCR² Therapeutics to Present at the Cantor Global Healthcare Conference

TCR² Therapeutics to Present at the Cantor Global Healthcare Conference Content Import Fri, 09/27/2019 - 08:01 TCR² Therapeutics to Present at the Cantor Global Healthcare Conference Sep 27, 2019 This release is a backfill from a News Wire General …

TCR² Therapeutics Reports Second Quarter 2019 Financial Results and Provides Corporate Update

Began dosing of TC-210 in the Phase 1/2 trial for patients with mesothelin-expressing solid tumors and an interim update anticipated in 4Q19/1Q20 Leading clinical sites participating in the TC-210 trial include Sarah Cannon Research Institute, MD Anderson Cancer Center and the National Cancer
Show more

TCR2 Therapeutics Frequently Asked Questions

  • When was TCR2 Therapeutics founded?

    TCR2 Therapeutics was founded in 2015.

  • Who are TCR2 Therapeutics key executives?

    TCR2 Therapeutics's key executives are Garry Menzel, Robert Hofmeister and Angela Justice.

  • How many employees does TCR2 Therapeutics have?

    TCR2 Therapeutics has 44 employees.

  • Who are TCR2 Therapeutics competitors?

    Competitors of TCR2 Therapeutics include Travecta Therapeutics, PolyPid and VBI Vaccines.

  • Where is TCR2 Therapeutics headquarters?

    TCR2 Therapeutics headquarters is located at 100 Binney St #710, Cambridge.

  • Where are TCR2 Therapeutics offices?

    TCR2 Therapeutics has an office in Cambridge.

  • How many offices does TCR2 Therapeutics have?

    TCR2 Therapeutics has 1 office.